Mitochondrial DNA diseases are rare inherited conditions that can affect many parts of the body, significantly shorten life expectancy. Currently, there is no cure.

For women carrying high levels of faulty mitochondrial DNA, existing reproductive options are not always effective or suitable.

Addressing this, the NIHR BRC: Newcastle infrastructure and project funding has supported this work since the first BRC award in 2007, when NIHR BRC: Newcastle established a research theme focused on mitochondrial abnormalities in ageing.

One of the top ten achievements reported in the final report of the first BRC award was the publication of establishing pronuclear transfer as a potential treatment for mitochondrial DNA disease in Nature in 2010, together with associated ethical and legislative developments.

This impact also builds on previous achievements supported through NIHR BRC funding, including the successful £4.5 million award of the Wellcome Trust Centre for Mitochondrial Research and the development of an IVF-based technique to reduce the risk of mitochondrial disease in 2011/2012.

This sustained investment provided the foundation for the scientific discoveries, policy developments and clinical translation that led to mitochondrial donation treatment becoming available in practice.

Impact at a glance

  • Researchers in Newcastle were the first to demonstrate that the transmission of mitochondrial DNA disease could be prevented using IVF-based techniques;
  • Contributed to the evidence, policy and legislative developments that led to mitochondrial donation becoming legal in the UK in 2015;
  • Supported the granting of the first HFEA treatment licence for mitochondrial donation at Newcastle Fertility Centre in 2017;
  • £4.5 million award of the Wellcome Trust Centre for Mitochondrial Research;
  • Translated mitochondrial donation treatment into clinical practice following decades of research;
  • Published the first clinical outcomes of the treatment in the New England Journal of Medicine;
  • Reported the birth of eight healthy babies and one ongoing pregnancy following treatment;
  • Supporting development of National Clinical Policy with NHS England and working with international partners to introduce the technique more widely.
 

Turning research into policy and practice

There are ways to reduce the risk of passing mitochondrial DNA disease to children, but these approaches do not work well, or are not possible, for women carrying very high levels of faulty mitochondrial DNA.

Researchers in Newcastle were the first to demonstrate that transmission of mitochondrial DNA disease could be prevented using IVF-based techniques. Alongside the scientific advances, researchers worked with patients, clinicians, regulators and policymakers to understand clinical need and support consideration of the treatment within the UK regulatory framework.

This included assessing which patients were most likely to benefit and working with the Department of Health to determine the cost of illness associated with mitochondrial disease. Evidence from this work informed parliamentary debates in 2015 on whether mitochondrial donation should be permitted in the UK. The House of Commons and House of Lords both passed the Regulations with substantial majorities.

In March 2017, The Human Fertilisation and Embryology Authority (HEFA) granted a treatment licence to the Newcastle Fertility Centre, part of the Newcastle upon Tyne Hospitals NHS Foundation Trust. This allowed a variation to the current clinical licence so that pro-nuclear transfer can be offered to reduce the risk of mothers transferring mitochondrial disease.

 

Benefits for patients and society

Decades of research at Newcastle, working closely with patients, clinicians, regulators and policymakers, led to the development and introduction of mitochondrial donation treatment (MDT), sometimes referred to as ‘three-parent IVF’.

The outcomes of mitochondrial donation treatment were reported in two papers published in the New England Journal of Medicine, documenting eight healthy babies born and one ongoing pregnancy. The findings attracted international attention and featured prominently across national and international media.

Mitochondrial donation treatment provides an option for women carrying high levels of faulty mitochondrial DNA who would otherwise have limited reproductive options to reduce the risk of transmitting disease.The work supports the Government's shift from sickness to prevention by helping to avoid serious inherited disease, benefiting patients, the NHS and the wider society.

 

What's next?

The team is working with NHS England to develop National Clinical Policy to support wider access to mitochondrial donation treatment across the UK and is collaborating with colleagues in Australia to introduce the technique internationally.

While clinical trials are ongoing and although outcomes are still emerging, the work has the potential to offer families affected by mitochondrial disease the chance to have healthy children and, if adopted more widely, could reduce future NHS costs by preventing lifelong care for affected children.

 

On BBC News